Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'

March 16, 2026 10:32 AM

Leerink Partners analyst David Risinger reiterated an Outperform rating and $90.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found